Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.58 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.58 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11251947 | 0.94 | HRH3 (0.67) | GRIN2BHRH3HRH4SLC18A3ALDH1A1 | |
| SCHEMBL14506713 | 0.92 | GRIN2B (0.55) | GRIN2BHRH3HRH4SLC18A3ALDH1A1 | |
| SCHEMBL12680890 | 0.92 | GRIN2B (0.55) | GRIN2BHRH3HRH4SLC18A3ALDH1A1 | |
| SCHEMBL13744978 | 0.92 | GRIN2B (0.55) | GRIN2BHRH3HRH4SLC18A3ALDH1A1 | |
| Bromide SCHEMBL11253051 | 0.92 | HRH3 (0.65) | GRIN2BHRH3HRH4SLC18A3ALDH1A1 | |
| SCHEMBL531089 | 0.92 | HRH3 (0.70) | GRIN2BHRH3HRH4SLC18A3ALDH1A1 | |
| SCHEMBL16367134 | 0.91 | GRIN2B (0.54) | GRIN2BHRH3HRH4SLC18A3ALDH1A1 | |
| SCHEMBL19195002 | 0.91 | GRIN2B (0.54) | GRIN2BHRH3HRH4SLC18A3ALDH1A1 | |
| SCHEMBL16607846 | 0.91 | GRIN2B (0.54) | GRIN2BHRH3HRH4SLC18A3ALDH1A1 | |
| SCHEMBL7603670 | 0.90 | HRH3 (0.73) | GRIN2BHRH3HRH4SLC18A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110818576-B | Secondary amine derivative synthesized by rare earth catalysis and preparation method thereof | 温州大学 | 2023-02-24 | — | — | CN | disclosed |
| CN-101146530-B | 3, 4-substituted pyrrolidine derivatives for the treatment of hypertension | NOVARTIS AG | 2011-05-18 | — | — | CN | disclosed |
| US-20100324091-A1 | Pyrazolone Derivative | KOWA COMPANY, LTD. (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2172458-A1 | PYRAZOLONE DERIVATIVE | Kowa Company, Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-7638648-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638648-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7468391-B2 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468391-B2 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| CN-101146530-A | 3, 4-substituted pyrrolidine derivatives for the treatment of hypertension | NOVARTIS AG (CH) | 2008-03-19 | — | — | CN | disclosed |
| CN-101115715-A | Pyrrolidine derivatives for the treatment of diseases associated with renin activity | NOVARTIS AG (CH) | 2008-01-30 | — | — | CN | disclosed |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-7226951-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-7226951-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-4048229-A | ANTAGONIST ACTIVITY | SMITHKLINE CORPORATION (US) | 1977-09-13 | — | — | US | disclosed |
| US-3976694-A | BETA-ADRENERGIC STIMULANT, BRONCHODILATOR | SMITHKLINE CORPORATION (US) | 1976-08-24 | — | — | US | disclosed |
| US-3961076-A | BRONCHODILATORS | SMITHKLINE CORPORATION (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324091-A1 | Pyrazolone Derivative | SERPINE1, SERPINC1, TFPI | GRIN2B 4254/4885HRH3 2064/4885HRH4 1106/4885 |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | GRIN2B 1018/4885HRH3 3876/4885HRH4 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.